---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-116111"
form_type: "8-K"
ticker: null
cik: "0001403708"
company_name: "Evoke Pharma Inc"
filed_at: "2024-10-22T23:59:59+00:00"
generated_at: "2026-05-30T11:34:03.213505+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Evoke Pharma appoints Benjamin Smeal as Class II director

## Summary
- Board appoints Benjamin Smeal as Class II director effective October 18, 2024, with term expiring at 2027 annual meeting.
- Smeal is a private investor; previously Associate Director at Willett Advisors (Michael Bloomberg's family office) and Senior Investment Analyst at Kenmare Management.
- Appointment made pursuant to nominating rights in letter agreement with Nantahala Capital Management dated September 27, 2024.
- Granted options to purchase 5,833 shares vesting in equal annual installments over three years; will receive cash compensation per non-employee director compensation program.
- Smeal also appointed to Audit, Compensation, and Nominating and Corporate Governance Committees; Board determined independent per Nasdaq rules.

## SEC filing metadata
- accession: 0000950170-24-116111
- form_type: 8-K
- cik: 0001403708
- company_name: Evoke Pharma Inc
- filed_at: 2024-10-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1403708/000095017024116111/0000950170-24-116111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1403708/000095017024116111/evok-20241018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-116111
- JSON: https://secwatch.observer/filing/0000950170-24-116111.json
- Plain text: https://secwatch.observer/filing/0000950170-24-116111.txt

## Key facts
- Executive change
  Benjamin Smeal was appointed as Class II director at Evoke Pharma Inc.
  - Action: appointed
  - Role: Class II director
  source text: On October 18, 2024, pursuant to the amended and restated bylaws of Evoke Pharma, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Benjamin Smeal to serve as a Class II director, effective October 18, 2024, with an initial term expiring at the Company’s 2027 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1403708/000095017024116111/0000950170-24-116111-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.